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Acquired bacterial resistance is common in
isolates from healthy persons and from patients
with community-acquired infections in develop-
ing countries, where the need for antibiotics is
driven by the high incidence of infectious disease
(1). Among isolates of diarrheal, respiratory, and
commensal enteric pathogens (2-5), resistance is
increasing, particularly to first-line, inexpen-
sive, broad-spectrum antibiotics (Table 1).
Furthermore, introduction of newer drugs (e.g.,
fluoroquinones) has been followed relatively
quickly by the emergence and dissemination of
resistant strains (5). The selection and spread of
resistant organisms in developing countries,
which can often be traced to complex
socioeconomic and behavioral antecedents,
contribute to the escalating problem of
antibiotic resistance worldwide.
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In developing countries, acquired bacterial resistance to antimicrobial agents is
common in isolates from healthy persons and from persons with community-acquired
infections. Complex socioeconomic and behavioral factors associated with antibiotic
resistance, particularly regarding diarrheal and respiratory pathogens, in developing
tropical countries, include misuse of antibiotics by health professionals, unskilled
practitioners, and laypersons; poor drug quality; unhygienic conditions accounting for
spread of resistant bacteria; and inadequate surveillance.
Table 1. Pathogens with a steadily increasing prevalence of acquired antibiotic resistance in developing tropical
countries
Pathogen Drug(s) Country (years) Ref.
Shigella flexneri, ampicillin, tetracycline, sulfonamides Bangladesh (1983-1990)   (6)
 S. dysenteriae    (alone or with trimethoprim), Brazil (1988-1993)   (7)
    nalidixic acid Rwanda (1983-1993)   (8)
Thailand (1981-1995)   (5)
Vibrio cholerae cotrimethoxazole, nalidixic Guinea-Bissau (1987-1995)   (9)
   acid, ampicillin India (1993-1995) (10)
Salmonella typhi ampicillin,  chloramphenicol, Bangladesh (1989-1993)   (3)
     cotrimethoxazole
Salmonella (nontyphoidal) cotrimethoxazole Thailand (1981-1995)   (5)
Enterotoxigenic Escherichia coli cotrimethoxazole Thailand (1981-1995)   (5)
Campylobacter fluoroquinolones Thailand (1987-1995)   (5)
Mycobacterium tuberculosis isoniazid, streptomycin, rifampicin Kenya (1981-1990) (11)
   (primary resistance) Morocco (1992-1994) (12)19 Vol. 5, No. 1, JanuaryFebruary 1999 Emerging Infectious Diseases
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Misuse of Antibiotics by Physicians in
Clinical Practice
Antibiotic use provides selective pressure
favoring resistant bacterial strains; inappropri-
ate use increases the risk for selection and
dissemination of antibiotic-resistant bacteria,
which are placed at a competitive advantage.
Therefore, one would expect that drugs more
commonly affected by bacterial resistance in
developing countries are generally inexpensive
and popular broad-spectrum agents (2-5,13).
However, the relationship between antibiotic
use and the emergence and spread of resistance
is complex. Antibiotic use in clinical practice
alone cannot explain the high frequency of
resistant organisms in developing countries
(14,15). Nevertheless, excessive clinical use (a
form of misuse) is at least partially responsible
for the escalating rates of resistance, especially
in hospital settings, worldwide. The unnecessary
prescription of antibiotics seen in industrialized
nations has also been documented in many
developing countries, particularly in cases of
acute infantile diarrhea and viral respiratory
infections (16-22). Clinical misuse of antibiotics
may be more common among private practitio-
ners than among public health personnel
private practitioners charge higher fees, the
demand for antibiotics seen in private patients is
higher, and more drugs are available in private
clinics than in public hospitals (23-25).
Several strategies have been proposed for
combating the inappropriate use of antibiotics by
clinicians (26). Antibiotic monitoring systems
and hospital formularies or antibiotic treatment
protocols often reduce antibiotic prescription
rates (24,27). Adoption of a national essential drug
list can limit the antibiotics available to prescribers
(28,29). However, implementation of these
strategies does not guarantee optimal antibiotic
use by clinicians in developing countries because
the irregular drug supply, availability of drugs
from unofficial sources, and financial constraints
also affect antibiotic choices (30-32).
Continuing medical education changes the
attitude of clinicians. Studies of antibiotic
misuse in Cuba and Pakistan (33,34) recommend
continuing medical education for health workers
as the single most important tool for combating
antibiotic misuse. A study in Zambia has
demonstrated the efficacy of education in
reducing antibiotic prescription rates (35).
However, education has not been successfully
implemented in many developing countries,
where too often, governments and health
workers cannot afford the time and money
required for continuing medical education (36).
Health workers in many developing coun-
tries have almost no access to objective health
information (24). Pharmaceutical company
representatives typically outnumber practitio-
ners and often adversely influence their
prescription habits (37), as reflected by sales of
nonessential drugs and drug combinations (38).
Drug labels and package inserts often fail to
provide accurate information (39), and in
industrialized countries, patients often pres-
sure physicians to prescribe antibiotics (19).
Misuse of Antibiotics by Unskilled
Practitioners
In many developing countries, well-trained
health personnel are scarce and cannot serve the
entire population, especially in rural areas.
Community health workers and others with
minimal training treat minor ailments (40). The
qualifications and training of community health
workers, as well as the quality of care they
provide, vary from country to country. Unskilled
personnel are less aware of the deleterious
effects of inappropriate antibiotic use. For
example, pharmacy technicians in Thailand
prescribed rifampicin for urethritis and tetracy-
cline for young children (41). Unqualified drug
sellers offer alternative drugs when the
prescribed drugs are out of stock or refill
prescriptions without consulting the prescriber
(42,43). In India, traditional healers often
dispense antibiotics (44). A high proportion of
patients in some developing countries are treated
by untrained practitioners simultaneously with
oral and injectable antibiotics administered with
contaminated needles and syringes (45-47) for
misdiagnosed noninfectious diseases (48).
Misuse of Antibiotics by the Public
In most developing countries, antibiotics can
be purchased without prescription, even when
the practice is not legal. In many African, Asian,
and Latin American countries, antibiotics are
readily available on demand from hospitals,
pharmacies, patent medicine stalls (drugstores),
roadside stalls, and hawkers (17,43,46,49-53). In
rural Bangladesh, for example, 95% of drugs
consumed for 1 month by more than 2,000 study
participants came from local pharmacies; only20 Emerging Infectious Diseases Vol. 5, No. 1, JanuaryFebruary 1999
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8% were prescribed by physicians (54). People
are encouraged to buy from unofficial distribu-
tors because drugs often are not available in
government hospitals (55). Drug vendors usually
have little or no knowledge of the required
dosage regimen, indications, or contraindications
(43,45,55). In markets and public transport in
West African countries such as Cameroon (49)
and Nigeria (Okeke and Lamikanra, pers. obs.),
the vendor (usually a medically untrained
salesman) tries to convince potential buyers to
purchase the drug, even if they are not ill.
To save time and keep drug-hunting to a
minimum, a patient may start at a source more
likely to stock the desired drug, forgoing the
expertise of a doctor. Unofficial sources are
generally more accessible than official sources.
For example, in Nepal, retail drug outlets are
four times as numerous as government health
posts and hospitals (46). Alternate sources offer
the option of purchasing small quantities of
medicines, while hospitals require purchase of
the complete 5- or 7-day antibiotic regimen
(17,43,52). The purchase of small samples is
exceedingly common, particularly for most
customers, who buy without prescription (52).
These subinhibitory antibiotic regimens predis-
pose for selection of resistant bacterial strains.
Antibiotic use in developing countries is
underestimated. The quantity of drugs distrib-
uted within a country is calculated under the
assumption that each person purchases a
complete regimen (56). However, medication can
be purchased in small aliquots from roadside
stalls, and distribution of locally produced or
counterfeit antibiotics is not recorded. The
motives for self-medication and antibiotic
overuse by laypersons are similar to those for
clinical abuse by health professionals: to cut
costs and act expeditiously to treat confirmed or
suspected bacterial infection (57). For example,
50% to 80% of Bangladeshi patients infected with
Shigella admitted that they had taken at least
one antibiotic in the 15 days before a hospital
visit (58), as had 18% to 70% of pediatric patients
with acute respiratory infection in two Chinese
studies (20,59). The proportion of patients who
self-medicate is probably higher, because
patients are often reluctant to admit having
taken antibiotics before visiting a hospital (60).
Common cultural beliefs about antibiotics
include the notions that there is a pill for every
symptom; antibiotics can heal many illnesses,
including dyspepsia and headaches; and injec-
tions are more powerful than pills. The misuse of
antibiotics frequently becomes integrated into
the local culture (62) (e.g., antibiotics are used to
prevent diarrhea after eating suspected contami-
nated foods or [by prostitutes] to prevent
sexually transmitted diseases [52,63]).
Another cause of antibiotic abuse and
selection for resistant bacteria is poor patient
compliance. First, physician-patient interactions
are often inadequate. They can be short (e.g., a
mean of 54 sec was recorded in a Bangladeshi
study [16]) and of poor quality (e.g., in Mexico,
poor patient-physician communication was
partially responsible for the noncompliance of
patients with antibiotic regimens [21]). Second,
because patients often travel long distances and
incur large expenses for medical care, they are
unlikely to return for follow-up visits. The reverse
situationthe prescriber visiting his patientis
difficult logistically, especially in rural Africa
(64). In addition, the patient may be unable to
read medicine labels. Finally, because many
drugs are expensive, indigent patients purchase
incomplete regimens whenever possible and
discontinue treatment when symptoms disap-
pear but before the pathogen is eliminated (52).
Poor Quality of Antibiotics
Lack of Quality Compliance and Monitoring
Besides the risk for therapeutic failure,
degradation products or adulterants in poor
quality antibiotics can produce subinhibitory
concentrations in vivo, which increase the
selection of resistant strains. Drugs that do not
comply with minimum standards are illegal in all
countries. However, the quality of many
antibiotics and other drugs in developing
countries is often below standards in the
formulary. In Nigeria for example, substandard
ampicillin, ampicillin/cloxacillin, tetracycline,
and oxytetracycline capsules have been detected
(53,65-67). In many cases, therapeutic failure is
the only indication of substandard drugs.
Analytic laboratories to detect substandard
drugs are uncommon, and when they exist,
health workers, distributors, and consumers are
often unaware of them.
Degraded Antibiotics
The shelf lives of drugs developed and
marketed in temperate countries are determined21 Vol. 5, No. 1, JanuaryFebruary 1999 Emerging Infectious Diseases
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by storage temperatures. During distribution in
tropical countries, conditions of transport and
storage are poorly controlled, and the drugs may
be degraded. Ballereau et al. (68) recorded
temperatures of 26°C to 40°C and 30% and 90%
humidity in Guinea-Bissau during a 2-year
period (temperatures of greater than 25°C can
degrade antibiotics). Many antibiotics, being
heat- and moisture-labile, are particularly
vulnerable. Of seven drugs that lost 10% or more
of their active constituents when stored in
pharmacies in Guinea-Bissau for 2 years, six
were antimicrobial drugs (68). Drug consign-
ments are exposed to such adverse conditions
during shipment (69) or at tropical ports while
they await lengthy port clearance. Drugs are
often handled by untrained workers who may
store them incorrectly. Hawkers and small
traders in Nigeria frequently display large glass
jars containing different types of antibiotic
capsules mixed together, fully exposed to harsh
sunlight and high ambient temperature and
humidity. In a Nigerian study of eight batches of
tetracycline capsules, only the batch obtained
directly from the manufacturer was not
excessively degraded and contained active drug
levels within formulary limits (Table 2) (53,70).
Studies conducted in Thailand and Nigeria
demonstrated similar degradation of chloro-
quine and amoxicillin (67,70).
Expired Antibiotics
Some pharmacologically active drugs pro-
duced in industrialized countries have expired
when distributed in developing countriesthey
were shipped at the end of the drugs shelf lives
or their clearance and distribution after
transcontinental shipment were delayed. Ex-
pired drugs may receive new labels, be dumped
without a label change, or be donated rather
than sold (71-73). Tax deductions and the cost of
liquidation are incentives for donating expired or
near-expired drugs. Effective enforcement of the
World Health Organization (WHO) guidelines on
drug donations may curtail such practices (74).
Counterfeit Drugs
Some drugs sold in developing countries do
not contain the concentration of active sub-
stances stated on their labels, even at the time of
manufacture. These counterfeit drugs flourish,
despite efforts of local regulatory agencies to stop
their production and distribution (75-77).
Approximately 65% of the 751 instances of
counterfeit  pharmaceuticals reported to WHO or
to Interpol from 28 countries in the past 15 years
were produced in developing countries (77).
Counterfeit drugs include products with little or
no active ingredients (e.g., in Nigeria, Indonesia,
Brazil,  Thailand, Bangladesh, Malaysia, and
Francophone  African countries [39,76,78,79]) or
products for which excipients have been replaced
by less expensive alternatives (e.g., substitution of
ethylene glycol for propylene glycol in pediatric
paracetamol formulations, which caused many
deaths in Nigeria, Argentina, Bangladesh,
India, and Haiti [76,78]). Counterfeit drugs,
like other counterfeit materials, compete
favorably in the markets of developing
countries. The analytic facilities available to
law enforcement agencies often cannot detect
these drugs before they reach the patient.
Multinational pharmaceutical companies,
which probably possess the best analytic
facilities for in-house quality assurance in
developing countries, try to detect counterfeit
drugs to protect their income and reputation;
however, such efforts are directed primarily at
counterfeits of these companies own products.
Because of the profusion of generic drugs in
developing countries, a substantial proportion
of counterfeit drugs go undetected.
Table 2. Source and quality of tetracycline capsules in a
Nigerian suburban town (compiled with data from [53])
  Tetra-
cycline
content Content Bioavail-
(% of label of ATCa ability
Sample Source claim) (%)  (%)b
C1 Manufacturerc 105.9   None    100
detected
C2 Hospital 107.5      5.3      63.4d
C3 Roadside stall 104.5      1.1      80.5d
C4 Pharmacy   66.1      2.4      65.2d
C5 Patent medicine   84.5      1.9      87.6d
  stall
C6 Roadside stall   67.8      1.5 Not tested
C7 Patent medicine   89.6      1.8 Not tested
  stall
aAnhydrotetracycline, one of four tetracycline degradation
products.
bMeasured from cumulative excretion of tetracycline in the
urine of five volunteers.
cReference standard obtained from the manufacturer.
dSignificantly different from C1 (p = 0.01, Wilcoxon signed
rank test).22 Emerging Infectious Diseases Vol. 5, No. 1, JanuaryFebruary 1999
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Adulterated Drugs
Herbal preparations in developing countries
are often adulterated with orthodox medica-
ments. For example, in one study, 24% of
Chinese herbal preparations marketed in
Taiwan contained one or more of such
adulterants (80). Although the adulteration of
such products with antibiotics has not been
reported, such practices may be common (81). A
Nigerian traditional healer, for example,
admitted to augmenting herbal preparations
with tetracycline from commercially available
capsules (82).
Bioinequivalent Antibiotics and
Biopharmaceutic Interactions
In the last 2 decades, the importance of
bioavailability has been underscored by the
recognition that chemically equivalent generic
drug formulations do not always deliver the
expected amount of drug to the bloodstream.
Slowly absorbed and acid-labile antibiotics are
particularly prone to bioinequivalence and
consequent therapeutic failure. In addition,
poorly absorbed antibiotics remain in the gut to
facilitate the selection of resistant organisms.
The few published studies from the developing
world have found bioinequivalence in antibi-
otic formulations, and the problem may be
widespread (Table 2) (53,83). Inexpensive
generic antibiotics commonly used in develop-
ing countries usually are not subject to
bioavailability studies.
The bioavailability of an antibiotic formula-
tion is modulated by conditions surrounding its
administration; conditions unique to developing
countries are rarely investigated. Drug combina-
tions used in the tropics but rarely elsewhere
may not be optimally absorbed. For example,
coadministration of chloroquine and ampicillin
lowers the bioavailability of ampicillin (84). A
Nigerian meal lowered the biologic availability of
orally administered nitrofurantoin (85). Chew-
ing of Khat, a popular Yemeni stimulant,
adversely affected the bioavailability of
ampicillin and amoxicillin (86). By contrast,
the Ayurvedic preparation Trikatu enhanced
the absorption of several drugs (87). Whether
traditional medicines with antimicrobial prop-
erties enhance antibiotic resistance is un-
known.
Dissemination of Resistant Organisms
Crowding and Unhygienic Conditions
Residents of developing countries often carry
antibiotic-resistant fecal commensal organisms
(13,88). Visitors to developing countries pas-
sively acquire antibiotic-resistant gut Escheri-
chia coli, even if they are not taking prophylactic
antibiotics, which suggests that they encounter a
reservoir of antibiotic-resistant strains during
travel (89). Apparently healthy people in
developing countries carry potentially patho-
genic, antibiotic-resistant organisms
asymptomatically (90). Several factors, such as
urban migration with crowding and improper
sewage disposal, encourage the exchange of
antibiotic-resistant organisms between people
and the exchange of resistance genes among
bacteria, thereby increasing the prevalence of
resistant strains. In Nigeria, resistant E. coli
isolates from persons in an urban metropolis
(Lagos) were significantly more likely to be
resistant to ampicillin and streptomycin (p < 0.05),
and possibly more resistant to sulphathiazole
and tetracycline (p < 0.10), than isolates from
residents of nearby smaller towns and villages
(Table 3) (91). Moreover, strains isolated from
Lagos were more likely to show resistance to 4 to
6 of 7 antibiotics tested, whereas strains from
rural areas were in most cases resistant to only 0
to 3 antibiotics (91).
In 1991, 80% of residents of developing
countries had no sanitary facilities for sewage
disposal (92). Pipe-borne water, often scarce in
developing countries, is not always potable. The
Table 3. Antibiotic resistance of Escherichia coli strains
isolated from residents of an urban area (Lagos) or rural/
suburban areas  (southwest Nigeria) (from [91])
Percentage of resistant isolates
Antimicrobial Urban Rural/suburban
agent (n = 30) (n = 44)
Ampicillina 53 27
Chloramphenicol 13 14
Streptomycina 63 32
Sulphathiazoleb 73 48
Tetracyclineb 87 64
Trimethoprim 53 41
aSignificant differences between the two groups at p <
0.05 (Chi-square test)
bSignificant differences between the two groups at p <
0.10 (Chi-square test)23 Vol. 5, No. 1, JanuaryFebruary 1999 Emerging Infectious Diseases
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development of sanitation and other facilities is
not always proportionate to the rapid rises in
urban populations (93,94). As urban migration
continues, overcrowding increases and hygiene
declines, increasing the probability of spread of
antibiotic-resistant and commensal pathogens.
Potable water, well-ventilated housing and
proper waste disposal should reduce infections,
the need for antibiotics, and subsequent
development of antibiotic resistance.
Because tropical conditions encourages the
survival of bacteria, more pathogens and
commensals are found in tropical environments
than in temperate climates (95). The warm and
humid tropical climate and the low levels of
health care, hygiene, and sanitation contribute
to a relatively high prevalence of infectious
disease in developing countries.
Inadequate Hospital Infection Control
Practices
Infection control practices in many hospitals
in developing countries are rudimentary and
often compromised by economic shortfalls and
opposing traditional values (96). The resulting
nidus of nosocomial pathogens and resistant
organisms may be disseminated to the outside
community. Improper disposal of hospital waste
accentuates such spread. Untreated hospital
waste in Uganda was often dumped into public
sewers or thrown into rubbish heaps ravaged by
scavengers (97).
Inadequate Surveillance
Susceptibility Testing and Surveillance
Information from routine susceptibility
testing of bacterial isolates and surveillance of
antibiotic resistance, which provides informa-
tion on resistance trends, including emerging
antibiotic resistance, is essential for clinical
practice and for rational policies against
antibiotic resistance. Bacterial infections are
often treated after they become life-threatening,
which encourages empirical selection of broad-
spectrum antibiotics (98,99). The antibiotic
susceptibility pattern of bacterial isolates in
much of the developing world is unknown, and
little guides empirical prescribing. Susceptibility
testing cannot be done readily because
equipment, personnel, and consumables are
scarce and expensive (59,100). In most all
infections, no clinical specimens are cultured.
Where available, community-based antibiotic
surveillance data may be useful to prescribers in
the absence of patient-specific antibiotic-
susceptibility results. For example, Ringertz et
al. (101) demonstrated that resistance among
respiratory pathogens was infrequent in parts of
Ethiopia. This information would help local
Ethiopian prescribers to treat such infections
with inexpensive, broad-spectrum antibiotics.
National surveillance programs for antibi-
otic resistance, the norm in industrialized
nations, are less common and less elaborate in
developing countries (4). Current inferences
about antibiotic resistance trends in developing
countries are based on a small number of reports,
generated by a handful of microbiology
laboratories in urban areasdata not represen-
tative of a country, because wide variations in
antibiotic resistance patterns may exist within
countries (Table 3). Moreover, surveillance
should be conducted regularly and continuously
because resistance rates can vary in one region of
a country over time (Table 1) (102).
Defective Antibiotic Susceptibility Assays
Well-standardized antibiotic susceptibility
assays provide more reliable results (103).
However, standard bacterial strains with which
to assay new batches of antibiotics or antibiotic
disks are not available in laboratories in many
developing countries. Delayed transportation
and breakdown of cold storage also affects the
quality of antibiotics used as diagnostic reagents.
Degraded antibiotic powders and antibiotic disks
used for susceptibility testing lead to exagger-
ated estimates of bacterial resistance levels. The
frequent recovery of bacteria resistant to the
beta-lactams or tetracyclines in tropical coun-
tries could reflect, in part, the temperature and
moisture lability of test reagents. Laboratory
scientists in developing countries face difficulties
in obtaining research supplies, which often
require them to improvise by, for example, using
injectable antibiotic formulations to measure
MICs when standard antibiotic powders are not
available. The report that clinical microbiologists
in developing countries make their own disks
from local blotting papers (104) illustrates how
improvisation can lead to inconsistent laboratory
results and unreliable data.24 Emerging Infectious Diseases Vol. 5, No. 1, JanuaryFebruary 1999
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Economic and Political Factors
Lack of resources hampers implementation
of most strategies against antibiotic resistance.
Statistics from the World Bank show that
developing countries spent $41 per person on
health in 1990, compared with the $1,500 per
person spent by industrialized countries.
Disease prevalence as measured by disability-
adjusted life years and by communicable disease
in particular is much greater in developing
than in industrialized countries (93,105-107).
As a result of such gross underfunding, the
drug supply is chronically inadequate or at
best erratic in health facilities in many
countries, including Nigeria (43,105,106).
Armed conflicts have recently led to a
breakdown in health services and sanitation and
rapid dissemination of resistant pathogens,
particularly in sub-Saharan Africa and Asia
(108,109,110). During an outbreak of cholera and
bacillary dysentery in Rwandan refugees,
resistance to multiple first-line antibiotics in
clinical isolates of Vibrio cholerae and Shigella
dysenteriae contributed to high death rates (109).
Even in developing countries not at war,
political corruption and mismanagement of
funds, personnel, and development programs
have created large populations living in abject
poverty and at high risk for infection (111).
Medical expenses, days lost from work, and
transportation costs account for substantial
economic loss. The cost of medical treatment,
even subsidized treatment, is beyond the means
of many patients. Poorly paid health workers
sometimes extort fees from patients (111). Thus,
persons with communicable diseases, unable to
afford medical treatment, may infect others.
Poverty also interferes with patient compliance,
which in turn promotes the emergence of
antibiotic resistance during short-term therapy
of acute infections and long-term therapy of
chronic infections, such as tuberculosis (111).
Combating the Problem of Antibiotic
Resistance
The recommendations of WHO for ensuring
proper drug use (79) can be adapted to combat
the escalation of community-acquired antibiotic
resistance in developing countries. The misuse of
antibiotics by health-care professionals, un-
skilled practitioners, and patients can be
alleviated by auditing antibiotics, limiting
antibiotic choice, developing prescription guide-
lines, and emphasizing continuing medical and
public education. The quality of antibiotics can
be improved by emphasizing quality compliance
and monitoring antimicrobial drugs manufac-
tured or dispensed. Such reforms will help
control substandard drugs that are degraded,
counterfeit, or bioinequivalent. Dissemination of
resistant organisms in the community can be
impeded by improved public sanitation and
hygienic practices and upgraded hospital
infection control. Finally, strategies to ensure
that these recommendations are adopted and
implemented under difficult economic and
political conditions can be formulated. Antimi-
crobial resistance will continue to escalate in
developing countries unless corrective measures
are instituted.
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